Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 4,085 Shares

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 4,085 shares of Apogee Therapeutics stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $46.94, for a total transaction of $191,749.90. Following the completion of the sale, the insider now owns 255,348 shares in the company, valued at approximately $11,986,035.12. This represents a 1.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, December 11th, Carl Dambkowski sold 4,540 shares of Apogee Therapeutics stock. The shares were sold at an average price of $48.76, for a total value of $221,370.40.
• On Wednesday, December 4th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The shares were sold at an average price of $46.07, for a total value of $307,056.55.
• On Wednesday, November 6th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $59.12, for a total value of $394,034.80.

Apogee Therapeutics Stock Performance

NASDAQ APGE opened at $47.77 on Friday. The stock has a market capitalization of $2.15 billion, a P/E ratio of -19.74 and a beta of 2.30. The business’s fifty day moving average is $49.13 and its two-hundred day moving average is $48.57. Apogee Therapeutics, Inc. has a 1 year low of $27.05 and a 1 year high of $72.29.

Institutional Investors Weigh In On Apogee Therapeutics

Several hedge funds have recently modified their holdings of APGE. JPMorgan Chase & Co. increased its stake in Apogee Therapeutics by 4.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 29,555 shares of the company’s stock worth $1,736,000 after purchasing an additional 1,212 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Apogee Therapeutics by 11.2% in the third quarter. Geode Capital Management LLC now owns 823,839 shares of the company’s stock worth $48,401,000 after acquiring an additional 82,978 shares in the last quarter. Barclays PLC raised its holdings in shares of Apogee Therapeutics by 369.2% during the third quarter. Barclays PLC now owns 365,046 shares of the company’s stock valued at $21,443,000 after acquiring an additional 287,243 shares during the period. Wellington Management Group LLP lifted its position in shares of Apogee Therapeutics by 35.7% in the 3rd quarter. Wellington Management Group LLP now owns 4,814,400 shares of the company’s stock valued at $282,798,000 after acquiring an additional 1,267,451 shares in the last quarter. Finally, Wexford Capital LP purchased a new position in Apogee Therapeutics during the 3rd quarter worth approximately $230,000. 79.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on APGE shares. Canaccord Genuity Group initiated coverage on shares of Apogee Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $89.00 price objective for the company. Wedbush increased their price objective on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the company an “outperform” rating in a report on Monday, December 2nd. Guggenheim reissued a “buy” rating on shares of Apogee Therapeutics in a report on Thursday, December 12th. Finally, Canaccord Genuity Group began coverage on Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 price target for the company. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, Apogee Therapeutics has a consensus rating of “Buy” and an average price target of $89.71.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.